Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2023-01-25 00:00:00 ET · period of report 2023-01-23 · accession 0001209191-23-004876 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-25 | 2023-01-23 | RCUS | Nuyten Dimitry SA | Chief Medical Off | A - Grant | $0.00 | +34.0K | 76.5K | +80% | $0 |
| D | 2023-01-25 | 2023-01-23 | RCUS | Nuyten Dimitry SA | Chief Medical Off | A - Grant | $0.00 | +138.2K | 138.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-23 | A | A | 34,000 | $0.00 | 76,500 | D | — | — | (F1) Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-01-23 | A | A | 138,200 | $0.00 | 138,200 | D | $22.02 · — to 2033-01-22 | 138,200 Common Stock | (F2) The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company. |